Skip to main content
. 2022 Aug 26;9:964650. doi: 10.3389/fcvm.2022.964650

Table 2.

Plasmatic levels of tested biomarkers in people living with HIV and controls depend on the absence or presence of coronary plaque.

Biomarker PLWH (n = 95) p-value Controls (n = 52) p-value
Absence of plaque Presence of plaque Absence of plaque Presence of plaque
GDF-15 (pg/mL) 764 (716–1,760) 1,037 (584–1,112) 0.04 415 (290–413) 640 (419–973) <0.001
FGF-21 (pg/mL) 172 (86–290) 224 (110–493) 0.44 189 (90–326) 184 (82–312) 0.73
GLP-2 (pg/mL) 1.9 (1.1–3.0) 1.8 (1.5–3.6) 0.84 2.8 (1.8–3.3) 2.2 (1.7–3.0) 0.60
suPAR (pg/mL) 2,062 (1,699–2,828) 2,772 (2,286–3,587) 0.003 1,864 (1,660–2,225) 2,331 (1,790–3,157) 0.08
hsCRP (mg/L) 5.0 (5.0–5.0) 5.0 (5.0–5.0) 0.14 5.0 (5.0–5.8) 5.0 (5.0–5.0) 0.54
Anti-CMV IgG (IU/mL) 27.2 (23.5–32.2) 28.7 (23.7–31.4) 0.62 4.9 (0.0–24.2) 13.6 (0.0–22.9) 0.68
Anti-EBV IgG (Genway U) 44.2 (35.9–47.3) 42.8 (30.2–47.8) 0.61 29.7 (16.8–42.6) 42.1 (33.7–48.0) 0.008

Medians and interquartile ranges are described. PLWH, people living with human immunodeficiency virus. The bold values indicate the significant values of p < 0.05.